Potential of FX06 to improve disease severity in Acute Respiratory Distress Syndrome patients (Ixion 2.0) Potenzial von FX06 die Krankheitsschwere von ARDS zu verbessern (Ixion 2.0)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

15 Sep 2024 This trial has been discontinued in Portugal, according to European Clinical Trials Database record
08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
15 Dec 2023 This trial has been completed in the Netherlands.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com